AOTI diabetic foot care therapy to be used by NHS
Ella Day | April 23, 2025 | News story | Research and Development | AOTI, Diabetes, diabetes, diabetic foot care, health economic study
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in the NHS supply chain. It treats diabetic foot ulcer (DFU) and significantly lowers overall diabetic foot care costs.
This adoption follows the publication of results from a health economic (HE) study in the Journal of Diabetic Complications that demonstrated that the adoption of the therapy within the NHS would reduce costs from recurrence, hospitalisations and amputations.
The effectiveness of TWO2 therapy has been demonstrated in AOTI’s recent randomised controlled trials (RCT) and real-world evidence studies (RWE). Together, they showed an 88% reduction in hospitalisations and a 71% reduction in amputations over 12-month periods.
Currently, almost 1% of the annual NHS budget is taken up by diabetic foot disease, with non-healing ulcers being the largest cost driver. DFU affects up to a third of diabetics, and these are leading causes of morbidity and lower extremity amputations among the diabetic population. TWO2 therapy proposes to significantly improve patient quality of life.
The framework agreement, under which goods and services are distributed, can run up to 48 months. TWO2 treatment is highly accessible as it can be administered by the patient at home.
Mike Griffiths, CEO of AOTI, stated: “It is exciting to see acknowledgement of the clinical and health economic benefits delivered by our TWO2 therapy.” He added: “Once implemented, patients across England will have easier access to our proven limb saving outcomes and the NHS can start to realise substantial cost savings.”
Ella Day
23/4/25
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI achieves broad market access in Germany for diabetic foot ulcer therapy
AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
